AbbVie Presents Positive Phase 2 Study Results for Zumilokibart in Atopic Dermatitis

NORTH CHICAGO, Ill., Sept. 30, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) has presented primary results from its ongoing Phase 2 APEX Part B study evaluating zumilokibart in adult patients with moderate to severe atopic dermatitis. The findings were shared as a late-breaker presentation at the European Academy of Dermatology and Venereology (EADV) Congress.

The study results showed that all three dose regimens of zumilokibart met the primary endpoint, demonstrating statistically significant improvements in Eczema Area and Severity Index -75 (EASI-75) response rates compared to placebo at Week 16. The APEX Part B study involved 346 participants randomized to receive low-, mid-, or high-dose zumilokibart or placebo over a 16-week induction period.

The mid-dose regimen was selected to advance into Phase 3 development due to its promising efficacy. This regimen also showed significantly greater improvements than placebo across key secondary endpoints, including skin clearance (EASI 90/100) and itch reduction (I-NRS), with notable improvements seen as early as Week 1.

Zumilokibart is a novel, half-life extended monoclonal antibody that targets interleukin-13 (IL-13). AbbVie stated that these results support the potential of zumilokibart to offer a differentiated treatment option for individuals living with atopic dermatitis, addressing ongoing unmet needs in the condition.